Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Top Cited Papers
- 1 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Reviews Immunology
- Vol. 21 (8), 475-484
- https://doi.org/10.1038/s41577-021-00578-z
Abstract
Most COVID-19 vaccines are designed to elicit immune responses, ideally neutralizing antibodies (NAbs), against the SARS-CoV-2 spike protein. Several vaccines, including mRNA, adenoviral-vectored, protein subunit and whole-cell inactivated virus vaccines, have now reported efficacy in phase III trials and have received emergency approval in many countries. The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs. After a single dose, the adenovirus vaccines elicit polyfunctional antibodies that are capable of mediating virus neutralization and of driving other antibody-dependent effector functions, as well as potent T cell responses. These data suggest that protection may require low levels of NAbs and might involve other immune effector mechanisms including non-NAbs, T cells and innate immune mechanisms. Identifying the mechanisms of protection as well as correlates of protection is crucially important to inform further vaccine development and guide the use of licensed COVID-19 vaccines worldwide.Keywords
This publication has 162 references indexed in Scilit:
- Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirusProceedings of the National Academy of Sciences of the United States of America, 2013
- RNAscope: A Novel in Situ RNA Analysis Platform for Formalin-Fixed, Paraffin-Embedded TissuesThe Journal of Molecular Diagnostics, 2012
- A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon ChallengeJournal of Virology, 2011
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008
- Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological StabilityMolecular Therapy, 2008
- Adenovirus vector induced innate immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine applicationsVirus Research, 2008
- A human SARS-CoV neutralizing antibody against epitope on S2 proteinBiochemical and Biophysical Research Communications, 2005
- The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core ComplexJournal of Virology, 2003
- The time course of the immune response to experimental coronavirus infection of manEpidemiology and Infection, 1990
- Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccinesJAMA, 1967